Phase II Study of Pegylated Ifna-2a (Pegasys) in Patients With Chronic Myeloid Leukemia Who Have Minimal Residual Disease While Receiving Therapy With Tyrosine Kinase Inhibitors

Trial Profile

Phase II Study of Pegylated Ifna-2a (Pegasys) in Patients With Chronic Myeloid Leukemia Who Have Minimal Residual Disease While Receiving Therapy With Tyrosine Kinase Inhibitors

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2014

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
    • 31 Jan 2012 New source identified and integrated (M.D. Anderson Cancer Center record; 2011-0184).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top